Direct Medical Cost of Hospitalized Patients With Hepatitis B Virus-related Diseases in Jiangsu Province

You-ren YU,Kai-jin ZHANG,Hua ZHANG,Hui JIN,Yong-feng YANG,Bo XIE,Si-min BAO,Yong-hua MA,Gui-yuan LIU
DOI: https://doi.org/10.3969/j.issn.1007-9572.2016.22.019
2016-01-01
Abstract:Objective To analyze the direct medical cost of hospitalized patients with hepatitis B virus( HBV) -related diseases, and to provide basis for further improving health insurance system of China. Methods 1 219 hospitalized patients with HBV - related diseases, who received treatment in two tertiary hospitals in Jiangsu Province from January to December 2014,were enrolled in this study. We performed a retrospective information searching of medical records based on hospital information system, and emphasized the investigation of patients' direct medical expenses and individual clinical information. Results Among the 1 219 hospitalized patients,there were 648 cases(53. 16%)with medical insurance;571 cases(46. 84%)at their own expenses;480 cases(39. 38%)received antiviral therapy,while 739 cases(60. 62%)did not receive antiviral therapy. Average direct medical cost of patients with HBV-related diseases was 20 874. 86 yuan,of which drug cost was 13 478. 90 yuan(64. 57%);average direct medical costs of patients with insurance and patients at their own expenses were 17 184. 94 yuan and 25 062. 37 yuan respectively;average direct medical costs of antiviral therapy patients and non -antiviral patients were 28 755. 85 yuan and 15 755. 95 yuan respectively. Conclusion Medicine costs cover a significant proportion of direct medical expenses of hospitalized patients with HBV -related diseases;related medical security policy in Jiangsu Province needs to be further improved;antiviral therapy should be taken as the preferred alternative of HBV -related diseases treatment.
What problem does this paper attempt to address?